Modern developments in germline pharmacogenomics for oncology prescribing

Area of Science:

• Oncology
• Pharmacogenomics
• Genetics

Background:

• Cancer patients face adverse drug events and treatment inefficacy despite genomic data integration.
• Somatic genomic platforms are prioritized over germline biomarkers in current oncology practice.
• Germline pharmacogenomic variants influence individual drug responses, impacting treatment outcomes.

Purpose of the Study:

• To review new pharmacogenomic evidence and oncology-specific dosing recommendations.
• To highlight the benefits of integrating both somatic and germline genomic information for personalized cancer care.
• To emphasize the role of germline pharmacogenomics in managing drug toxicity and efficacy.

Main Methods:

• Review of recent pharmacogenomic literature and clinical guidelines.
• Analysis of FDA label guidance and international society recommendations.
• Synthesis of evidence on germline genetic variants and their impact on anticancer drug response.

Main Results:

• Established pharmacogenes (e.g., TPMT, UGT1A1, DPYD) have long-standing clinical relevance.
• New pharmacogenes and variants are identified, impacting novel anticancer agents like targeted therapies and antibody-drug conjugates.
• Pharmacogenomic data is increasingly informing clinical action and dosing strategies.

Conclusions:

• Integrating germline pharmacogenomic information is crucial for optimizing personalized oncology care.
• Multidisciplinary collaboration is essential for implementing pharmacogenomics in clinical practice.
• Expanded consideration of germline genetics promises to further enhance the safety and effectiveness of cancer treatment.